How Pyrilutamide, a hair loss treatment, has improved texture and regrowth of hair without any side effects for users, who are encouraged to post progress photos.
The user shared their 10-year hair loss journey, discussing treatments like oral minoxidil, oral finasteride, and LLLT, and ultimately deciding on a hair transplant. They also explored the possibility of having alopecia areata incognita and advised seeking multiple opinions before surgery.
The user has been managing hair loss with microneedling, Nutrafol, topical finasteride/minoxidil foam, LLLT, and Nizoral, and plans to add oral minoxidil. They are seeing improvement and are cautious about using oral finasteride due to past gynecomastia concerns.
Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.
A user applied pyrilutamide for 6 months without hair regrowth and is considering stopping due to cost and lack of results. Another user suggests switching to finasteride, which is cheaper and has shown regrowth for them.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
The conversation discusses the potential risks and considerations of purchasing raw Clascoterone powder from Made-In-China to create a DIY topical solution for hair loss. Concerns include fake products, low purity, and contamination, with a request for experiences and advice on reliable suppliers.
Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.
A 33-year-old male is experiencing thinning at the temples and hairline, with increased shedding over the past year. The user suspects androgenetic alopecia (AGA) despite AI suggesting a maturing hairline.
A user experienced severe side effects, including symptoms of congestive heart failure, after using excessive doses of minoxidil for beard growth. They stopped using it due to financial reasons, but still suffer from lingering symptoms and are advised to seek medical attention.
A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
A 19-year-old male with seborrheic dermatitis (SD) experienced significant hair loss and uses keto shampoo, zinc, and Nizoral to manage it. He inquires about the potential for regrowth and whether adding finasteride would help.
Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.
This user has conducted data scraping of 365 Reddit posts on the hairloss drug Pyrilutamide over the last year to analyse efficacy and side effects. The findings, which are available in a 19 page report with graphs, suggest that 22% of Pyrilutamide users experience positive results while 63% experience symptoms. A larger analytics project is proposed for other drugs with enough demand.
A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.
The user changed their hair loss treatment in October/November, experienced increased shedding, and now sees no new hair growth, with a worsening condition and a possible bald spot. They also have severe seborrheic dermatitis, which may be affecting their scalp and hair loss.
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.
Increased scalp itching during shedding phases while on finasteride treatment may coincide with hair regrowth and recovery. This suggests that itching might not always indicate continued hair loss and could encourage persistence with the treatment.
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.